Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

Dario Ribero; Huamin Wang; Matteo Donadon; Daria Zorzi; Melanie B. Thomas; Cathy Eng; David Z. Chang; Steven A. Curley; Eddie K. Abdalla; Lee M. Ellis; Jean Nicolas Vauthey

doi:10.1002/cncr.23099

Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

Dario Ribero, Huamin Wang, Matteo Donadon, Daria Zorzi, Melanie B. Thomas, Cathy Eng, David Z. Chang, Steven A. Curley, Eddie K. Abdalla, Lee M. Ellis, Jean Nicolas Vauthey

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. METHODS. A total of 105 consecutive patients treated preoperatively with 5FU/OX chemotherapy with (n = 62) or without (n = 43) bevacizumab were analyzed. The response to chemotherapy was evaluated by pathologic analysis of tumor viability (percentage of viable tumor in relation to tumor surface area). The incidence and grade of hepatic sinusoidal dilation were also investigated. RESULTS. Bevacizumab-containing regimens significantly reduced the degree of tumor viability compared with 5FU/OX-only chemotherapy (32.9% vs 45.3%; P = .02). After stratification according to the magnitude of tumor viability, a higher proportion of patients treated with bevacizumab than without had

Original language	English
Pages (from-to)	2761-2767
Number of pages	7
Journal	Cancer
Volume	110
Issue number	12
DOIs	https://doi.org/10.1002/cncr.23099
Publication status	Published - Dec 15 2007

Keywords

Bevacizumab
Colorectal liver metastases
Hepatotoxicity
Oxaliplatin
Sinusoidal dilatation
Tumor response

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1002/cncr.23099

Cite this

Ribero, D., Wang, H., Donadon, M., Zorzi, D., Thomas, M. B., Eng, C., Chang, D. Z., Curley, S. A., Abdalla, E. K., Ellis, L. M., & Vauthey, J. N. (2007). Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer, 110(12), 2761-2767. https://doi.org/10.1002/cncr.23099

Ribero, D, Wang, H, Donadon, M, Zorzi, D, Thomas, MB, Eng, C, Chang, DZ, Curley, SA, Abdalla, EK, Ellis, LM & Vauthey, JN 2007, 'Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases', Cancer, vol. 110, no. 12, pp. 2761-2767. https://doi.org/10.1002/cncr.23099

@article{5788fbb128b046f6b8b51d805b577f07,

title = "Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases",

abstract = "BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. METHODS. A total of 105 consecutive patients treated preoperatively with 5FU/OX chemotherapy with (n = 62) or without (n = 43) bevacizumab were analyzed. The response to chemotherapy was evaluated by pathologic analysis of tumor viability (percentage of viable tumor in relation to tumor surface area). The incidence and grade of hepatic sinusoidal dilation were also investigated. RESULTS. Bevacizumab-containing regimens significantly reduced the degree of tumor viability compared with 5FU/OX-only chemotherapy (32.9% vs 45.3%; P = .02). After stratification according to the magnitude of tumor viability, a higher proportion of patients treated with bevacizumab than without had ",

keywords = "Bevacizumab, Colorectal liver metastases, Hepatotoxicity, Oxaliplatin, Sinusoidal dilatation, Tumor response",

author = "Dario Ribero and Huamin Wang and Matteo Donadon and Daria Zorzi and Thomas, {Melanie B.} and Cathy Eng and Chang, {David Z.} and Curley, {Steven A.} and Abdalla, {Eddie K.} and Ellis, {Lee M.} and Vauthey, {Jean Nicolas}",

year = "2007",

month = dec,

day = "15",

doi = "10.1002/cncr.23099",

language = "English",

volume = "110",

pages = "2761--2767",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "12",

}

TY - JOUR

T1 - Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

AU - Ribero, Dario

AU - Wang, Huamin

AU - Donadon, Matteo

AU - Zorzi, Daria

AU - Thomas, Melanie B.

AU - Eng, Cathy

AU - Chang, David Z.

AU - Curley, Steven A.

AU - Abdalla, Eddie K.

AU - Ellis, Lee M.

AU - Vauthey, Jean Nicolas

PY - 2007/12/15

Y1 - 2007/12/15

N2 - BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. METHODS. A total of 105 consecutive patients treated preoperatively with 5FU/OX chemotherapy with (n = 62) or without (n = 43) bevacizumab were analyzed. The response to chemotherapy was evaluated by pathologic analysis of tumor viability (percentage of viable tumor in relation to tumor surface area). The incidence and grade of hepatic sinusoidal dilation were also investigated. RESULTS. Bevacizumab-containing regimens significantly reduced the degree of tumor viability compared with 5FU/OX-only chemotherapy (32.9% vs 45.3%; P = .02). After stratification according to the magnitude of tumor viability, a higher proportion of patients treated with bevacizumab than without had

AB - BACKGROUND. The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology. METHODS. A total of 105 consecutive patients treated preoperatively with 5FU/OX chemotherapy with (n = 62) or without (n = 43) bevacizumab were analyzed. The response to chemotherapy was evaluated by pathologic analysis of tumor viability (percentage of viable tumor in relation to tumor surface area). The incidence and grade of hepatic sinusoidal dilation were also investigated. RESULTS. Bevacizumab-containing regimens significantly reduced the degree of tumor viability compared with 5FU/OX-only chemotherapy (32.9% vs 45.3%; P = .02). After stratification according to the magnitude of tumor viability, a higher proportion of patients treated with bevacizumab than without had

KW - Bevacizumab

KW - Colorectal liver metastases

KW - Hepatotoxicity

KW - Oxaliplatin

KW - Sinusoidal dilatation

KW - Tumor response

UR - http://www.scopus.com/inward/record.url?scp=37048998995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37048998995&partnerID=8YFLogxK

U2 - 10.1002/cncr.23099

DO - 10.1002/cncr.23099

M3 - Article

C2 - 17960603

AN - SCOPUS:37048998995

VL - 110

SP - 2761

EP - 2767

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -

Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this